Anthem Biosciences Limited is a Bangalore-based, technology-driven **Contract Research, Development, and Manufacturing Organization (CRDMO)**. Founded in **2006**, the company has evolved into a fully integrated "one-stop" partner for global pharmaceutical innovators and emerging biotech firms. Anthem distinguishes itself through its dual-stream capability in both **New Chemical Entities (NCE)** and **New Biological Entities (NBE)**, managing the entire drug lifecycle from early-stage discovery to commercial-scale manufacturing. The company listed on the **NSE and BSE on July 21, 2025**, marking a transition into a high-growth public entity with a robust balance sheet and a "build-in-advance" infrastructure strategy. --- ### **Core Business Architecture & Modality Capabilities** Anthem operates through two primary business streams: **CRDMO Services** (Discovery and Development) and **Specialty Ingredients** (Manufacturing of specialized chemical and biological products). The company is one of the few Indian entities capable of handling complex modalities at commercial scale. | Modality | Current Operational Status | Scale | | :--- | :--- | :--- | | **Small Molecules** | Fully Operational | Commercial | | **Peptides** | Commissioned & Operational | Commercial (16 kL capacity) | | **Antibody-Drug Conjugates (ADCs)** | Commissioned | Commercial-ready | | **RNA & Lipids** | Operational | Development & Commercial batches | | **Monoclonal Antibodies (mAbs)** | Research & Development stage | Lab-scale (Ready for expansion) | #### **High-Growth Verticals** * **Antibody-Drug Conjugates (ADC):** Anthem offers full-spectrum ADC capabilities, including the synthesis of **Cytotoxic Warheads**, **Linkers**, and the **Conjugation** process. The pipeline currently features **5 to 6 early-stage projects** and **1 late-stage project**. * **Peptides & GLP-1s:** A pioneer in the space since 2012, Anthem manages **8-9 innovator peptide programs**. It is currently leveraging this expertise to partner with innovators on **GLP-1** and other complex molecules. * **Discovery Services:** The company maintains a high volume of "shots on goal" through medicinal chemistry, biology, DMPK, and process R&D, ensuring a steady flow of projects into the manufacturing funnel. --- ### **Strategic Infrastructure & Greenfield Expansion** Anthem follows a proactive capacity-building strategy to capture projects transitioning from **Phase 2 to Phase 3**. Most operations are concentrated in the **Harohalli (Bangalore)** industrial cluster. #### **Manufacturing Footprint** * **Unit II:** Recently completed with a final block of **76 kL** custom synthesis capacity. * **Unit III (NeoAnthem):** A state-of-the-art facility featuring R&D labs, pilot labs, and a **2.5 kL** high-potent facility. A dedicated **16 kL** peptide facility is also operational here. * **Unit III (Fermentation):** Large-scale fermentation infrastructure expected to be fully commissioned by the **end of 2025**. * **Unit IV:** A new **30-acre** greenfield site where ground was broken in mid-2025 to support long-term volume requirements. #### **Subsidiary Management: Neoanthem Lifesciences** Anthem executes its large-scale manufacturing through its wholly-owned subsidiary, **Neoanthem**. Financial commitment to this subsidiary is significant: * **Equity Conversion:** Anthem converted **₹375 Crores** of debt into equity in Neoanthem (comprising **₹100 Crores** in Feb 2025 and **₹275 Crores** in Feb 2026). * **Financial Support:** The Board has approved a financial assistance limit of **₹550 Crores** and issued corporate guarantees of **₹49 Crores** to **Citi Bank N.A.** and **Federal Bank** for working capital. --- ### **Financial Performance & Revenue Momentum** The company maintains a high-margin profile with a strong **Net Cash** position, driven by the consistent ramp-up of the CRDMO segment. #### **9M FY26 Financial Summary (Consolidated)** | Metric | Value (INR Crore) | Margin (%) | | :--- | :--- | :--- | | **Revenue from Operations** | **1,513.4** | - | | **EBITDA** | **671.2** | **41.5%** | | **Profit After Tax (PAT)** | **402.0** | **24.8%** | | **Net Cash Position** | **1,231.2** | - | * **Segmental Contribution:** The **CRDMO** business is the primary engine, contributing **₹1,259.9 Crore (~83%)** of total revenue, while **Specialty Ingredients** contributed **₹253.5 Crore**. * **Profitability Trends:** While **Q2 FY26** saw peak EBITDA margins of **44.5%**, **Q3 FY26** remained strong at **41.8%**. * **Other Income:** 9M FY26 results were bolstered by **₹104.6 Crore** in other income and **₹40.5 Crore** in operating incentives (Forex gains and RoDTEP). --- ### **Market Strategy & Risk Mitigation** Anthem’s geographic and operational strategies are designed to insulate the business from global volatility. * **Geographic Buffer:** A significant portion of sales is directed to **Europe**. By supplying advanced intermediates to Big Pharma for global formulation, Anthem mitigates the risk of direct **US-specific tariffs**. * **Asset-Heavy Competitive Advantage:** The company prefers Greenfield expansion over US-based acquisitions due to the high cost and **7-8 year approval cycles** for new facilities abroad. * **Regulatory Headwinds:** The company is navigating the notification of the **four new Indian Labour Codes (Nov 2025)**. * **Exceptional Item:** Anthem recorded a non-recurring charge of **₹25.4 Crore** in FY26 to account for provisions related to the new Code on Wages and Social Security. * **Compliance:** Management is actively monitoring **State Rules** to ensure full alignment with the consolidated labor framework. --- ### **Investment Outlook** Anthem Biosciences is positioned as a high-barrier-to-entry player in the Indian CDMO landscape. With **Unit III** fermentation coming online and **Unit IV** under construction, the company is prepared for the next wave of commercialization in **ADCs, Peptides, and Biologics**. Its transition from a debt-heavy expansion phase to a **Net Cash** position of **₹1,231.2 Crore** provides the liquidity necessary to pursue inorganic growth or further accelerate greenfield projects as client demand dictates.